Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study)

References

• Mannucci PM, Tuddenham EG. The hemophilias – from royal genes to gene therapy. N Engl J Med. 2001;344(23):1773–1779. doi:10.1056/NEJM200106073442307
   PubMed Web of Science ®Google Scholar
• Lieuw K. Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches? J Blood Med. 2017;8:67–73. doi:10.2147/JBM.S103796
   PubMed Web of Science ®Google Scholar
• White GC 2nd, Rosendaal F, Aledort LM, et al. Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85(3):560. doi:10.1055/s-0037-1615621
   PubMed Web of Science ®Google Scholar
• Berntorp E, Astermark J, Bjorkman S, et al. Consensus perspectives on prophylactic therapy for haemophilia: summary statement. Haemophilia. 2003;9(Suppl 1):1–4. doi:10.1046/j.1365-2516.9.s1.17.x
   PubMed Web of Science ®Google Scholar
• Ljung RC. Prophylactic infusion regimens in the management of hemophilia. Thromb Haemost. 1999;82(2):525–530. doi:10.1055/s-0037-1615875
   Web of Science ®Google Scholar
• Iorio A, Marchesini E, Marcucci M, et al. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011;(9):CD003429. doi:10.1002/14651858.CD003429.pub4
   Web of Science ®Google Scholar
• Mannucci PM. The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade. Haemophilia. 2012;18(Suppl 2):2–7. doi:10.1111/j.1365-2516.2012.02794.x
   Web of Science ®Google Scholar
• Calvez T, Chambost H, Claeyssens-Donadel S, et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood. 2014;124(23):3398–3408. doi:10.1182/blood-2014-07-586347
   PubMed Web of Science ®Google Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
   PubMed Web of Science ®Google Scholar
• Ettingshausen CE, Kreuz W. Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia. 2006;12(Suppl 6):102–106. doi:10.1111/j.1365-2516.2006.01373.x
   PubMed Web of Science ®Google Scholar
• Garagiola I, Palla R, Peyvandi F. Risk factors for inhibitor development in severe hemophilia A. Thromb Res. 2018;168:20–27. doi:10.1016/j.thromres.2018.05.027
   PubMed Web of Science ®Google Scholar
• Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus. 2011;9(4):366–370. doi:10.2450/2011.0092-10
   PubMed Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Ljung R, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231–239. doi:10.1056/NEJMoa1208024
   PubMed Web of Science ®Google Scholar
• Chalmers EA, Brown SA, Keeling D, et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia. 2007;13(2):149–155. doi:10.1111/j.1365-2516.2006.01418.x
   PubMed Web of Science ®Google Scholar
• Goudemand J, Rothschild C, Demiguel V, et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood. 2006;107(1):46–51. doi:10.1182/blood-2005-04-1371
   PubMed Web of Science ®Google Scholar
• Gringeri A, Monzini M, Tagariello G, et al. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate. Haemophilia. 2006;12(2):128–132. doi:10.1111/j.1365-2516.2006.01201.x
   Web of Science ®Google Scholar
• Mancuso ME, Mannucci PM, Rocino A, et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost. 2012;10(5):781–790. doi:10.1111/j.1538-7836.2012.04691.x
   PubMed Web of Science ®Google Scholar
• Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9(4):418–435. doi:10.1046/j.1365-2516.2003.00780.x
   PubMed Web of Science ®Google Scholar
• Ammollo CT, Semeraro F, Vitulli A, et al. FVIII/VWF complex displays a greater pro-haemostatic activity than FVIII preparations devoid of VWF: study in plasma and cell-based models. Haemophilia. 2020;26(4):e151–e160. doi:10.1111/hae.14008
   Web of Science ®Google Scholar
• Skotnicki A, Lissitchkov TJ, Mamonov V, et al. Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study). Thromb Res. 2016;137:119–125. doi:10.1016/j.thromres.2015.10.014
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products; 2019. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-human-plasma-derived-factor-viii-products-revision-2_en.pdf. Accessed August 2, 2019.
   Google Scholar
• Bjorkman S, Blanchette VS, Fischer K, et al. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. J Thromb Haemost. 2010;8(4):730–736. doi:10.1111/j.1538-7836.2010.03757.x
   PubMed Web of Science ®Google Scholar
• Bjorkman S, Oh M, Spotts G, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119(2):612–618. doi:10.1182/blood-2011-07-360594
   PubMed Web of Science ®Google Scholar
• Swystun LL, Ogiwara K, Rawley O, et al. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients. Blood. 2019;134(11):880–891. doi:10.1182/blood.2019000190
   PubMed Web of Science ®Google Scholar
• Klukowska A, Windyga J, Batorova A. Clinical efficacy of a novel VWF-containing FVIII concentrate, Wilate®, in the prophylaxis and treatment of bleeding episodes in previously treated haemophilia A patients. Thromb Res. 2011;127(3):247–253. doi:10.1016/j.thromres.2010.11.030
   Web of Science ®Google Scholar
• Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):607–615. doi:10.1111/hae.12438
   PubMed Web of Science ®Google Scholar
• Petrini P, Valentino LA, Gringeri A, et al. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8(2):237–246. doi:10.1586/17474086.2015.1002465
   PubMed Web of Science ®Google Scholar
• Giangrande PLF, Hermans C, O’Mahony B, et al. European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis. 2018;13(1):66. doi:10.1186/s13023-018-0800-z
   Web of Science ®Google Scholar
• Oldenburg J, Schroder J, Brackmann HH, et al. Environmental and genetic factors influencing inhibitor development. Semin Hematol. 2004;41(1 Suppl 1):82–88. doi:10.1053/j.seminhematol.2003.11.016
   PubMed Web of Science ®Google Scholar
• Astermark J, Berntorp E, White GC, et al. The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7(3):267–272. doi:10.1046/j.1365-2516.2001.00510.x
   Web of Science ®Google Scholar
• van der Bom JG, Mauser-Bunschoten EP, Fischer K, et al. Age at first treatment and immune tolerance to factor VIII in severe hemophilia. Thromb Haemost. 2003;89(3):475–479. doi:10.1055/s-0037-1613376
   Web of Science ®Google Scholar
• Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL Cohort Study. Blood. 2007;109(11):4648–4654. doi:10.1182/blood-2006-11-056291
   PubMed Web of Science ®Google Scholar
• Peyvandi F, Garagiola I. Product type and other environmental risk factors for inhibitor development in severe hemophilia A. Res Pract Thromb Haemost. 2018;2(2):220–227. doi:10.1002/rth2.12094
   PubMed Web of Science ®Google Scholar